Cirius Therapeutics Stock

ciriustx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $68.9MM

Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's insulin sensitizer is used to treat nonalcoholic steatohepatitis which is characterized by buildup of fat and inflammation in the liver, may be accompanied by fibrosis and can progress to life-threatening cirrhosis or liver cancer, enabling healthcare providers to treat patients of liver and metabolic diseases and avoid recurrence of nonalcoholic steatohepatitis.

Register To Buy and Sell Shares

For more details on financing and valuation for Cirius Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Cirius Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cirius Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Robert Baltera Jr.
Chief Executive Officer, President and Board Member
Howard Dittrich MD
Chief Medical Officer
Brian Farmer
Chief Financial Officer and Chief Business Officer
Jerry Colca Ph.D
Chief Scientific Officer

Board Members

David Van Andel
Nilesh Kumar Ph.D
Novo Holdings
Dennis Fenton Ph.D
Elaine Sun
Robert Zerbe
Daniel Estes Ph.D
Frazier Healthcare Partners
Michael Jandernoa
Robert Baltera Jr.

Frequently Asked Questions About Cirius Therapeutics’ Stock

Can you buy Cirius Therapeutics’ stock?
Cirius Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Cirius Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Cirius Therapeutics’ stock?
Yes, you can sell stock of a private company like Cirius Therapeutics. Forge can help you sell your Cirius Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Cirius Therapeutics’ stock price?
Cirius Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Cirius Therapeutics’ private market stock price with Forge Data.
What is Cirius Therapeutics’ stock ticker symbol?
Cirius Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Cirius withdraws $86M IPO as vaunted 'Year of NASH' draws to brutal close
Cirius Therapeutics didn't wait for the government shutdown to end before it filed its IPO in January. It was, as JP Morgan analysts had predicted the month prior,
Updated on: May 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.